Reports preliminary FY25 revenue $2.3B, consensus $2.22B. Approximately 923,600 tests were processed in the fourth quarter compared to 792,800 tests in the fourth quarter of 2024, an increase of 17%. Approximately 3,525,500 tests were processed in FY25 compared to 3,064,600 tests in the full year 2024, an increase of approximately 15%. “2025 was a record year for oncology, organ health and women’s health,” said Steve Chapman, CEO of Natera (NTRA). “The fourth quarter was particularly strong, with excellent growth in volume, revenue and gross margins. We believe we are well positioned to continue building on this momentum in 2026 and beyond.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Wayfair upgraded, Instacart initiated: Wall Street’s top analyst calls
- Natera price target raised to $280 from $240 at TD Cowen
- Exelixis, Natera announce collaboration on STELLAR-316 trial
- Natera initiated with a Buy at Citi
- Natera: Leading MRD Position, Expanding Margins, and Premium Valuation Support Buy Rating and $300 Target